Denali Therapeutics Reports Q3 Net Income of $70.126 Million
Story updates
09:04:08 PM UTC
SquawkNews
DENALI THERAPEUTICS Q3 OPERATING INCOME USD -126.751 MILLION
09:14:52 PM UTC
SquawkNews
Denali Therapeutics reported 2026 revenue of $17.78 million and net income of $70.13 million, compared with no revenue and a net loss of $126.9 million in 2025. Diluted EPS was $0.37, versus a loss per share of $0.74 in the prior-year period.Financial Highlights¹ Reported as “Product revenue, net”…
09:21:19 PM UTC
SquawkNews
Denali Therapeutics reported third-quarter 2026 net product revenue of $17.8 million and net income of $70.1 million, which included a one-time gain from selling a Priority Review Voucher. The company ended the quarter with approximately $1.0 billion in cash, cash equivalents and marketable securit…